Candesartan: widening indications for this angiotensin II receptor blocker?

Bibliography

• Kannel William B, Vasan Ramachandran S, Levy D. Is the relation of systolic blood pressure to risk of cardiovascular disease continuous and graded, or are there critical values? (From the National Heart, Lung, and Blood Institute's Framingham Study and the Department of Preventive Medicine). Hypertension 2003;42:453-456
   PubMedGoogle Scholar
• Kannel William B. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging 2003;20(4):277-86
   PubMedGoogle Scholar
• The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. ESC guidelines. Eur Heart J 2008;29:22388-442
   Web of Science ®Google Scholar
• Diabetes UK. Diabetes State of the Nations 2006: progress made in delivering the national diabetes framework. Available from: www.diabetes.org.uk/documents/reports/sotn2006_full.pdf [Accessed 13 June 2009]
   Google Scholar
• Securing good health for the whole Population, Wanless report. HM Treasury. Available from: http://www.hm-treasury.gov.uk/consult_wanless04_final.htm [Accessed 13 June 2009]
   Google Scholar
• Yorkshire & Humber Public Health Observatory. PBS diabetes population prevalence model – phase 2. Available from: http://www.yhpho.org.uk/ default.aspx [Accessed 13 June 2009]
   Google Scholar
• Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006;6:58
   PubMed Web of Science ®Google Scholar
• Viberti G, Marshall S, Beech R, et al. Report on renal disease in diabetes. Diabet Med 1996;13(9 Suppl 4):S6-12
   Google Scholar
• Manson J, Colditz G, Stampfer M, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991;151:1141-7
   PubMed Web of Science ®Google Scholar
• Stamler J, Vaccaro O, Neaton J, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44
   PubMed Web of Science ®Google Scholar
• Carey R, Siragy H. Newly recognised components of the renin angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24;261-71
   PubMed Web of Science ®Google Scholar
• Unger T, Li J. The role of the rennin–angiotensin–aldosterone system in heart failure. Renin Angiotensin Aldosterone Syst 2004;5;S7
   PubMed Web of Science ®Google Scholar
• Demrs C, Mody A, Teo K, Mckelvie R. ACE inhibitors in heart failure: what more do we need to know? Am J Cardiovasc Drugs 2005;5(6):351-9
   PubMedGoogle Scholar
• Mitchell K, Braam B, Navar L. Hypertensiogenic mechanisms mediated by renal actions of rennin–angiotensin system. Hypertension 1992;19(Suppl 1):I18-27
   Web of Science ®Google Scholar
• Gradman A. AT1-receptor blockers: differences that matter. J Hum Hypertension 2002;16(Suppl 3):S9-16
   Google Scholar
• Van Liefde I, Vauquelin G. Sartan AT (1) receptor interaction: in vitro evidence for insurmountable antagonism and inverse agonsim. Moll Cell Endocrinol 2009;302(2):237-43
   PubMed Web of Science ®Google Scholar
• Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 2000;56(2):135-40
   PubMed Web of Science ®Google Scholar
• Product Monograph Atacand Test. Available from: http://www.astrazeneca.ca/documents/ProductPortfolio/ ATACAND_PM_en.pdf [Accessed 13 June 2009]
   Google Scholar
• Uchida S, Watanabe H, Nishio S, et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther 2003;74(5):505-8
   PubMed Web of Science ®Google Scholar
• Federal Drug Agency user information. Available from: www.fda.gov/cder/foi/label/1998/20838lbl.pdf [Accessed 13 June 2009]
   Google Scholar
• Severs P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil in patients with mild to moderate hypertension. J Hum Hypertens 1997;11(Suppl 2):S69-73
   Google Scholar
• New Zealand emedicines and medical devices safety authority data sheet. Available from: www.medsafe.govt.nz/profs/datasheet/a/Atacandtab.htm [Accessed 13 June 2009]
   Google Scholar
• Severs P. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker. J Hum Hypertens 1997;11(Suppl 2):S91-5
   Google Scholar
• Vit D, White W, Ridley E, et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens 2001;15:475-80
   PubMedGoogle Scholar
• Macgregor G, Viskopfer J, Antonios T, Feng J. (UK and Israel Candesartan Investigators): Efficacy of candesartan cilexetil alone or in combination with amlodipine and hydrochlorothiazide in moderate-to-severe hypertension. Hypertension 2000;36:454
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Derosa G. CANDIA (Candesartan and diuretic vs. amlodipine in hypertensive patients) Study Group: efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J Renin Angiotensin Aldosterone Syst 2007;8(3):139-44
   PubMed Web of Science ®Google Scholar
• Oparil S, Levine J, Zushke C, et al. Effects of candesartan cilexetil in patients with severe systemic hypertension. Candesartan Cilexetil Study Investigators. Am J Cardiol 1999;84(3):289-93
   PubMed Web of Science ®Google Scholar
• Oparol S. Candesartan cilexetil in combination with low-dose hydrochlorothiazide is effective in severe hypertension. Am J Cardiol 1999;84(10A):35S-41S
   Google Scholar
• Sever P. Clinical profile of the novel angiotensin II type I blocker candesartan cilexetil. J Hypertens Suppl 1997;15(6):S9-12
   Google Scholar
• Lithell P, Hansson L, Skoog I, et al. SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21(5):875-86
   PubMed Web of Science ®Google Scholar
• Papademetriou V, Farsang C, Elmfeldt D, et al. Study on cognition and prognosis in the elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004;44(6):1175-80
   PubMed Web of Science ®Google Scholar
• Schrader J, Luders S, Kuschewski A, et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003;34(7):1699-703
   PubMed Web of Science ®Google Scholar
• Yusuf S, Ostergreb J, Gerstein H, et al. Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005;112(1):48-53
   PubMed Web of Science ®Google Scholar
• Chobanian Abakris G, Black H, Cushman W, et al. The National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206
   PubMedGoogle Scholar
• Papadopolous D, Makris T, Papademtriou V. Is it time to treat pre-hypertension? Hypertens Res 2008;31(9):1681-6
   PubMedGoogle Scholar
• Egan B, Nesbitt S, Julius S. Prehypertension: should we be treating with pharmacologic therapy? Ther Adv Cardiovasc Dis 2008;2(4):305-14
   PubMedGoogle Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273(18):1450-6
   PubMed Web of Science ®Google Scholar
• Pfeffer M, Swedberg K, Granger C, et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362(9386):759-66
   PubMed Web of Science ®Google Scholar
• McMurray J, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362(9386):767-71
   PubMed Web of Science ®Google Scholar
• Krum H, Carson P, Farsang C, et al. Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT. Eur J Heart Fail 2004;6(7):937-45
   PubMed Web of Science ®Google Scholar
• White H, Aylward P, Huang Z, et al. VALIANT Investigators. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Circulation 2005;112(22):3391-9
   PubMedGoogle Scholar
• Yusuf F, Teo K, Pogue J, et al. (ONTARGET Investigators). Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358(15):1547-59
   PubMed Web of Science ®Google Scholar
• Ducharme A, Swedberg K, Pfeffer M, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J 2006;152(1):86-92
   PubMed Web of Science ®Google Scholar
• Maggioni A, Latini R, Carson P, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-7
   PubMed Web of Science ®Google Scholar
• Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9
   PubMed Web of Science ®Google Scholar
• Jandeleit-Dahm K, Tikellis C, Reid C, et al. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005;23(3):463-73
   PubMed Web of Science ®Google Scholar
• Jiaqing Shao, Iwashita N, Ikeda F, et al. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on β-cell function. Biochemical and biophysical research communications and morphology in db/db mice. Biochem Biophys Res Commun 2006;344(4):1224-33
   PubMedGoogle Scholar
• Gillespie E, White C, Kardas M, et al. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes. Diabetes Care 2005;28:2261-6
   PubMed Web of Science ®Google Scholar
• Scheen A. Prevention of type 2 diabetes mellitus through inhibition of the Renin–angiotensin system. Drugs 2004;64(22):2537-65
   PubMed Web of Science ®Google Scholar
• Elliott W, Meyer P. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 2007;369(9557):201-7
   PubMedGoogle Scholar
• Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008;51(2):393-8
   PubMed Web of Science ®Google Scholar
• Kasanuki H, Hagiwara N, Hosoda S, et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009;30(10):1203-12
   PubMed Web of Science ®Google Scholar
• Suzuki K, Nakagawa O, Aizawa Y. Improved early-phase insulin response after candesartan treatment in hypertensive patients with impaired glucose tolerance. Clin Exp Hypertens 2008;30(5):309-14
   PubMed Web of Science ®Google Scholar
• Bosh J, Yusuf S, Gerdtein H, et al. DREAM Trial Investigators Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355(15):1551-62
   PubMedGoogle Scholar
• Califf R, Boolell M, Hafner S, et al. NAVIGATOR Study Group. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008;156(4):623-32
   PubMed Web of Science ®Google Scholar
• Mitchell K, Braam B, Navar L. Hypertensiogenic mechanisms mediated by renal actions of rennin–angiotensin system. Hypertension 1992;19(Suppl 1):I18-27
   Web of Science ®Google Scholar
• Lewis E, Hunsicker L, Bain R, Rohde R. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329(20):1456-62
   PubMed Web of Science ®Google Scholar
• Lovell H. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev 2001;1:CD002183
   Google Scholar
• Strippoli G, Craig M, Craig J. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2005;4:CD004136
   Google Scholar
• Lewis E, Hunsicker L, Clarke W, et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345(12):851-60
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper M, Dezeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345(12):861-9
   PubMed Web of Science ®Google Scholar
• Parving H, Lehnert H, et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345(12):870-8
   PubMed Web of Science ®Google Scholar
• Stripolli G, Craig M, Deeks J, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004;329(7470):828
   PubMedGoogle Scholar
• Mackenzie H, Troy J, Rennke H, Brenner B. TCV 116 prevents progressive renal injury in rats with extensive renal mass ablation. J Hypertens Suppl 1994;12(9):S11-6
   Google Scholar
• Kumagai H, Skata K, Matsuura T, et al. Comparison of ARB and ACEI for renoprotection in chronic glomerulonephritis. Nippon Rinsho 2002;60(10):2005-13
   PubMedGoogle Scholar
• Murayama S, Hirano T, Sakaue T, et al. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003;26(6):453-8
   PubMedGoogle Scholar
• Rossing K, Christensen P, Hansen B, et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study. Diabetes Care 2003;26(1):150-5
   PubMed Web of Science ®Google Scholar
• Weinberg A, Zappe D, Ashton M, Weinberg M. Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: a pilot study. Am J Nephrol 2004;24(3):340-5
   PubMed Web of Science ®Google Scholar
• Schmeider R, Klingbeil A, Fleischmann E, et al. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 2005;16(10):3038-45
   PubMedGoogle Scholar
• Burgess E, Muirhead N, Decotret P, et al. the SMART (Supra Maximal Atacand Renal Trial) Investigators. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009;20(4):893-900
   PubMed Web of Science ®Google Scholar
• Kurokawa K, Abe K, Saruta T, et al. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. J Renin Angiotensin Aldosterone Syst 2002;3(3):167-75
   PubMedGoogle Scholar
• Omoto K, Tanabe K, Tokumoto K, et al. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation 2003;76(8):1170-4
   PubMed Web of Science ®Google Scholar
• Nutahara K, Higashihara E, Horie S, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2005;99(1):c18-23
   Google Scholar
• Mogensen C, Neldam S, Tikkanen I, et al. for the CALM Study Group. Randomised controlled trial of dual blockade of rennin–angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM)study. BMJ 2000;321:1440-4
   PubMed Web of Science ®Google Scholar
• Kincaid-Smith P, Fairley K, Packham D. Dual blockade of the rennin–angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant 2004;19(9):2272-4
   PubMed Web of Science ®Google Scholar
• Luno J, Barrio V, Goicoechea M, et al. Effects of dual blockade of the rennin–angiotensin system in primary proteinuric nephropathies. Kidney Int Suppl 2002;82:S47-52
   PubMedGoogle Scholar
• Rossing K, Christensen P, Jensen B, Parving H. Dual blockade of the rennin–angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25(1):95-100
   PubMed Web of Science ®Google Scholar
• Andersen N, Poulsen P, Knudsen S, et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study. Diabetes Care 2005;28(2):273-7
   PubMed Web of Science ®Google Scholar
• Mann J, Scmeider R, Mcqueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372(9638):547-53
   PubMed Web of Science ®Google Scholar
• Chatuverdi N, Porta M, Klein R, et al. DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372(9647):1394-402
   PubMedGoogle Scholar
• Sjolie A, Klein R, Porta M, et al. DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372(9647):1385-93
   PubMed Web of Science ®Google Scholar